利用血浆生物标志物区分额颞叶变性tau蛋白与TDP-43
这项回顾性横断面研究基于2009至2020年数据,纳入234例参与者,评估血浆GFAP/NfL比值区分尸检确诊的FTLD-tau与FTLD-TDP的能力。训练样本中该比值区分两者的AUC为0.89(90%CI 0.82-0.95),高于单独GFAP(AUC=0.65)或NfL(AUC=0.75);在独立验证样本中应用尸检 derived 阈值,敏感度为0.84,特异度为0.81。结论认为血浆GFAP/NfL比值可能有助于区分FTLD-tau与FTLD-TDP。
要点
- 血浆GFAP/NfL比值区分FTLD-tau与FTLD-TDP的AUC为0.89(90%CI 0.82-0.95)。
- 该比值区分能力高于单独GFAP(AUC=0.65)或单独NfL(AUC=0.75)。
- 验证样本中应用尸检 derived 阈值,敏感度0.84、特异度0.81。
核心结论
- 血浆GFAP/NfL比值可能区分FTLD-tau与FTLD-TDP。
研究设计与样本
- 回顾性横断面研究,数据来自2009至2020年宾夕法尼亚大学综合神经退行性疾病数据库,中位随访2(IQR 0.3-4.2)年。
- 349例有血浆数据的参与者中234例符合纳入标准:31例对照、141例训练样本、62例验证样本。
- 训练样本为尸检确诊和家族性FTLD患者,验证样本为临床诊断的PSPS-tau或ALS-TDP患者。
主要发现
- 训练样本中FTLD-tau患者较FTLD-TDP患者年长(均值[SD] 65.8[8.29]岁 vs 62.3[7.82]岁;均差3.57;95%CI 0.67-6.48;P=.02),性别分布相似(男性27/46[59%] vs 51/95[54%];χ²₁=0.14;P=.70)。
- 验证样本中PSPS-tau患者较ALS-TDP患者年长(均值[SD] 69.3[7.35]岁 vs 54.6[10.17]岁;均差14.71;95%CI 10.19-19.23;P<.001),男性比例更低(9/31[29%] vs 22/31[71%];χ²₁=9.3;P=.002)。
- 血浆GFAP/NfL比值区分FTLD-tau与FTLD-TDP的AUC为0.89(90%CI 0.82-0.95),敏感度0.73(90%CI 0.65-0.89),特异度0.89(90%CI 0.78-0.98)。
- 单独GFAP的AUC为0.65(90%CI 0.54-0.76),单独NfL的AUC为0.75(90%CI 0.64-0.85)。
- 验证样本中应用尸检 derived 血浆GFAP/NfL阈值,敏感度0.84(90%CI 0.66-0.94),特异度0.81(90%CI 0.62-0.91)。
关键数值与推荐
- 训练样本通过ROC曲线确定GFAP/NfL比值的最佳cut point(Youden指数),并在独立验证样本中评估。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Biomarkers are lacking that can discriminate frontotemporal lobar degeneration (FTLD) associated with tau (FTLD-tau) or TDP-43 (FTLD-TDP). OBJECTIVE: To test whether plasma biomarkers glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), or their ratio (GFAP/NfL) differ between FTLD-tau and FTLD-TDP. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cross-sectional study included data from 2009 to 2020 from the University of Pennsylvania Integrated Neurodegenerative Disease Database, with a median (IQR) follow-up duration of 2 (0.3-4.2) years. The training sample was composed of patients with autopsy-confirmed and familial FTLD; nonimpaired controls were included as a reference group. The independent validation sample included patients with FTD with a clinical diagnosis of progressive supranuclear palsy syndrome (PSPS) associated with tau (PSPS-tau) or amytrophic lateral sclerosis (ALS) associated with TDP-43 (ALS-TDP). In patients with FTLD with autopsy-confirmed or variant-confirmed pathology, receiver operating characteristic (ROC) curves tested the GFAP/NfL ratio and established a pathology-confirmed cut point. The cut point was validated in an independent sample of patients with clinical frontotemporal dementia (FTD). Data were analyzed from February to July 2022. EXPOSURES: Clinical, postmortem histopathological assessments, and plasma collection. MAIN OUTCOMES AND MEASURES: ROC and area under the ROC curve (AUC) with 90% CIs evaluated discrimination of pure FTLD-tau from pure FTLD-TDP using plasma GFAP/NfL ratio; the Youden index established optimal cut points. Sensitivity and specificity of cut points were assessed in an independent validation sample. RESULTS: Of 349 participants with available plasma data, 234 met inclusion criteria (31 controls, 141 in the training sample, and 62 in the validation sample). In the training sample, patients with FTLD-tau were older than patients with FTLD-TDP (FTLD-tau: n = 46; mean [SD] age, 65.8 [8.29] years; FTLD-TDP: n = 95; mean [SD] age, 62.3 [7.82] years; t84.6 = 2.45; mean difference, 3.57; 95% CI, 0.67-6.48; P = .02) but with similar sex distribution (FTLD-tau: 27 of 46 [59%] were male; FTLD-TDP: 51 of 95 [54%] were male; χ21 = 0.14; P = .70). In the validation sample, patients with PSPS-tau were older than those with ALS-TDP (PSPS-tau: n = 31; mean [SD] age, 69.3 [7.35] years; ALS-TDP: n = 31; mean [SD] age, 54.6 [10.17] years; t54.6 = 6.53; mean difference, 14.71; 95% CI, 10.19-19.23; P < .001) and had fewer patients who were male (PSPS-tau: 9 of 31 [29%] were male; ALS-TDP: 22 of 31 [71%] were male; χ21 = 9.3; P = .002). ROC revealed excellent discrimination of FTLD-tau from FTLD-TDP by plasma GFAP/NfL ratio (AUC = 0.89; 90% CI, 0.82-0.95; sensitivity = 0.73; 90% CI, 0.65-0.89; specificity = 0.89; 90% CI, 0.78-0.98), which was higher than either GFAP level alone (AUC = 0.65; 90% CI, 0.54-0.76) or NfL levels alone (AUC = 0.75; 90% CI, 0.64-0.85). In the validation sample, there was sensitivity of 0.84 (90% CI, 0.66-0.94) and specificity of 0.81 (90% CI, 0.62-0.91) when applying the autopsy-derived plasma GFAP/NfL threshold. CONCLUSIONS AND RELEVANCE: The plasma ratio of GFAP/NfL may discriminate FTLD-tau from FTLD-TDP.
引用
- Cousins KAQ, Shaw LM, Chen-Plotkin A, et al. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers. JAMA Neurol. 2022. PMID: 36215050. doi:10.1001/jamaneurol.2022.3265
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。